Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Michael J Fox Foundation has granted $400,000 to Impax Pharmaceuticals for the ongoing clinical research Parkinson's disease experimental drug carbidopa-levodopa extended release (CD-LD ER) product IPX066.
Subscribe to our email newsletter
The grant will help the company in the intended dosing conversion study of CD-LD ER to IPX066 in pateints with advanced PD pateints.
The company is also set to conduct ASCEND-PD comparative study of IPX066 and carbidopa-levodopa and entacapone.
Michael J Fox Foundation Research Programs director Brian Fiske said by collaborating with Impax Pharmaceuticals to develop additional clinical data about IPX066, they hope to gather important information for physicians treating PD and their patients.